These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

721 related articles for article (PubMed ID: 34580494)

  • 1. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication.
    Chu J; Xing C; Du Y; Duan T; Liu S; Zhang P; Cheng C; Henley J; Liu X; Qian C; Yin B; Wang HY; Wang RF
    Nat Metab; 2021 Nov; 3(11):1466-1475. PubMed ID: 34580494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Fatty Acid Lipid Metabolism Nexus in COVID-19.
    Tanner JE; Alfieri C
    Viruses; 2021 Jan; 13(1):. PubMed ID: 33440724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of VPS34 and fatty-acid metabolism suppress SARS-CoV-2 replication.
    Williams CG; Jureka AS; Silvas JA; Nicolini AM; Chvatal SA; Carlson-Stevermer J; Oki J; Holden K; Basler CF
    Cell Rep; 2021 Aug; 36(5):109479. PubMed ID: 34320401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice.
    Shang C; Zhuang X; Zhang H; Li Y; Zhu Y; Lu J; Ge C; Cong J; Li T; Tian M; Jin N; Li X
    Virol J; 2021 Feb; 18(1):46. PubMed ID: 33639976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice.
    Paull JRA; Luscombe CA; Castellarnau A; Heery GP; Bobardt MD; Gallay PA
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection.
    Lieber CM; Kang H-J; Sobolik EB; Sticher ZM; Ngo VL; Gewirtz AT; Kolykhalov AA; Natchus MG; Greninger AL; Suthar MS; Plemper RK
    J Virol; 2024 Sep; 98(9):e0090524. PubMed ID: 39207133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice.
    Muturi E; Hong W; Li J; Yang W; He J; Wei H; Yang H
    Int J Antimicrob Agents; 2022 Jan; 59(1):106499. PubMed ID: 34929295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of host cell serine protease inhibitor MM3122 against SARS-CoV-2 for treatment and prevention of COVID-19.
    Boon ACM; Bricker TL; Fritch EJ; Leist SR; Gully K; Baric RS; Graham RL; Troan BV; Mahoney M; Janetka JW
    J Virol; 2024 May; 98(5):e0190323. PubMed ID: 38593045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus.
    Vitner EB; Achdout H; Avraham R; Politi B; Cherry L; Tamir H; Yahalom-Ronen Y; Paran N; Melamed S; Erez N; Israely T
    J Biol Chem; 2021; 296():100470. PubMed ID: 33639165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.
    Mirabelli C; Wotring JW; Zhang CJ; McCarty SM; Fursmidt R; Pretto CD; Qiao Y; Zhang Y; Frum T; Kadambi NS; Amin AT; O'Meara TR; Spence JR; Huang J; Alysandratos KD; Kotton DN; Handelman SK; Wobus CE; Weatherwax KJ; Mashour GA; O'Meara MJ; Chinnaiyan AM; Sexton JZ
    Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34413211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular host factors for SARS-CoV-2 infection.
    Baggen J; Vanstreels E; Jansen S; Daelemans D
    Nat Microbiol; 2021 Oct; 6(10):1219-1232. PubMed ID: 34471255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus.
    Dong W; Mead H; Tian L; Park JG; Garcia JI; Jaramillo S; Barr T; Kollath DS; Coyne VK; Stone NE; Jones A; Zhang J; Li A; Wang LS; Milanes-Yearsley M; Torrelles JB; Martinez-Sobrido L; Keim PS; Barker BM; Caligiuri MA; Yu J
    J Virol; 2022 Jan; 96(1):e0096421. PubMed ID: 34668775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition.
    Bestion E; Zandi K; Belouzard S; Andreani J; Lepidi H; Novello M; Rouquairol C; Baudoin JP; Rachid M; La Scola B; Mege JL; Dubuisson J; Schinazi RF; Mezouar S; Halfon P
    Viruses; 2022 Jan; 14(1):. PubMed ID: 35062337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
    Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of ACTN4 as a novel antiviral target against SARS-CoV-2.
    Zhu M; Huang F; Sun H; Liu K; Chen Z; Yu B; Hao H; Liu H; Ding S; Zhang X; Liu L; Zhang K; Ren J; Liu Y; Liu H; Shan C; Guan W
    Signal Transduct Target Ther; 2024 Sep; 9(1):243. PubMed ID: 39289355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 aberrantly elevates mitochondrial bioenergetics to induce robust virus propagation.
    Shin HJ; Lee W; Ku KB; Yoon GY; Moon HW; Kim C; Kim MH; Yi YS; Jun S; Kim BT; Oh JW; Siddiqui A; Kim SJ
    Signal Transduct Target Ther; 2024 May; 9(1):125. PubMed ID: 38734691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding Severe Acute Respiratory Syndrome Coronavirus 2 Replication to Design Efficient Drug Combination Therapies.
    Ortega JT; Zambrano JL; Jastrzebska B; Liprandi F; Rangel HR; Pujol FH
    Intervirology; 2020; 63(1-6):2-9. PubMed ID: 33099545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The global succinylation of SARS-CoV-2-infected host cells reveals drug targets.
    Liu Q; Wang H; Zhang H; Sui L; Li L; Xu W; Du S; Hao P; Jiang Y; Chen J; Qu X; Tian M; Zhao Y; Guo X; Wang X; Song W; Song G; Wei Z; Hou Z; Wang G; Sun M; Li X; Lu H; Zhuang X; Jin N; Zhao Y; Li C; Liao M
    Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2123065119. PubMed ID: 35858407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice.
    Winkler ES; Chen RE; Alam F; Yildiz S; Case JB; Uccellini MB; Holtzman MJ; Garcia-Sastre A; Schotsaert M; Diamond MS
    J Virol; 2022 Jan; 96(1):e0151121. PubMed ID: 34668780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
    Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.